

Dr. Jane Doe  
Paul-Ehrlich-Str. 23  
72076 TÜBINGEN  
GERMANY

<b>Patient</b>	XXX, XX (*DD.MM.YYYY)
<b>Sex</b>	Male
<b>Patient-ID</b>	#
<b>Sample receipt</b>	xxx
<b>Material</b>	DNA
<b>Report date</b>	xxx

## Genetic analysis report – XXX, XX (\*DD.MM.YYYY)

**Indication** Suspected schwannomatosis or neurofibromatosis; patient with several schwannomas  
**Order** Panel Diagnostics: Neurofibromatosis type 1 and related disorders (whole exome enrichment)

Dear Dr. Doe,

Thank you for your request for molecular genetic analysis.

### RESULTS

- **Detection of a pathogenic variant in gene *LZTR1*, which confers a susceptibility for schwannomatosis which is consistent with your patient's symptoms.**
- Based upon current scientific knowledge, we did not identify any reportable copy number variants which are likely to be causative for your patient's disease.

Gene	Variant	Zygosity	Heredity	MAF (%)	<i>in silico</i> Prediction	Classification
<i>LZTR1</i>	c.2286delG; p.Asn763Thrfs*4	het.	AD, AR	-	-	pathogenic

#### Information for table interpretation:

**AD:** Describes a trait or disorder requiring only one copy of a gene variant at a particular locus in order to express an observable phenotype. Single heterozygous gene variants can only be causative for the phenotype if the disorder follows the **autosomal dominant** mode of inheritance.

**AR:** Describes a trait or disorder requiring the presence of two copies of a gene variant at a particular locus in order to express an observable phenotype. In **autosomal recessive** disorders, a single heterozygous variant in one gene cannot by itself be causative for the observable phenotype.

**XL:** X-linked mode of inheritance

**mitochondrial:** gene encoded in the mitochondrial DNA. Information on degree of heteroplasmy (heteropl. or homopl.), frequency and read count (variant/total reads).

**MAF:** The **minor allele frequency** describes the least frequent allele at a specific locus in a given population. The less frequently a variant occurs, the more likely it is pathogenic; however, the prevalence and mode of inheritance of any particular disease must be considered. For mitochondrial variants, the population frequency (MAF column) is based on the homoplasmic frequency within a reference population (gnomAD).

***in silico* Prediction:** The ACMG (American College of Medical Genetics) guidelines recommend using prediction programs to assess the possible pathogenicity of a variant. Each program calculates its predictions based upon different criteria, and the correspondence between a prediction and the actual functional effect of a variant is variable. **These predictions may therefore not serve as the sole basis for the evaluation of pathogenicity.**

**Classification:** Refers to the possible pathogenicity of a variant, but does not necessarily provide clear evidence of clinical significance. Variants are evaluated based upon current data and specific criteria, and are then classified as follows: pathogenic, likely pathogenic, and uncertain significance. **All variants for which clinical relevance cannot be conclusively confirmed or excluded are referred as variants of unknown clinical significance.**

## INTERPRETATION

### **LZTR1, c.2286delG; p.Asn763Thrfs\*4 (het.), NM\_006767.4**

OMIM / Reference	Phenotype	Heredity
616564	Noonan syndrome (NS) 10	AD
605275	Noonan syndrome (NS) 2	AR
<b>615670</b>	<b>Schwannomatosis 2, susceptibility to</b>	<b>AD</b>

The **LZTR1** gene encodes a protein that belongs to the functionally diverse superfamily of BTB/POZ proteins, which control fundamental cellular processes (e.g. regulation of chromatin conformation, cell cycle) (GeneCards). Numerous pathogenic missense variants, splice variants, frameshift, and nonsense variants in the **LZTR1** gene have been published in association with schwannomatosis. **LZTR1**-associated schwannomas most often affect peripheral nerves and spinal nerves – but also unilateral vestibular schwannoma can occur. The most common clinical symptom is localized or diffuse pain. Approximately 30% of **LZTR1**-related schwannomatosis occur due to *de novo* variants. Incomplete penetrance has been described (Smith et al., 2015, PMID: 25480913; Dhamija et al., 2018, PMID: 29517885, GeneReviews).

The variant **c.2286delG; p.Asn763Thrfs\*4** in gene **LZTR1** has been detected in heterozygous state in your patient. This variant creates a shift in the reading frame, which will most likely result in nonsense-mediated decay of the mRNA transcript. Therefore, it is consistent with a described pathomechanism for pathogenic **LZTR1** variants associated with schwannomatosis. To the best of our knowledge, this variant has not been mentioned in a clinical context (Pubmed, ClinVar, HGMD Professional). However, for gene **LZTR1** several frameshift variants located further downstream have already been described as causative in patients with schwannomatosis (Piotrowski et al., 2014, PMID: 24362817; Paganini et al., 2015, PMID: 25335493).

**The detected pathogenic variant in LZTR1 is consistent with a susceptibility to schwannomatosis 2 and with the symptoms of your patient.**

Additional variants may be present within regions which were not analyzed (e.g. introns, promoter and enhancer regions and long repeats). A lower specificity enrichment and/or inaccurate variant calling cannot be ruled out for homologous regions with multiple genomic copies. The occurrence of low frequency somatic mosaicism cannot be reliably assessed using a pipeline optimized for germline variant detection, and may therefore remain undetected. Moreover, detection of large deletions and duplications is not guaranteed by next-generation high-throughput sequencing. Although unlikely, it is also possible that the classification of variants may change in the future due to improvements in scientific understanding.

## GENETIC RELEVANCE

Your patient is heterozygous for a pathogenic variant in gene **LZTR1**. This may be of relevance for family planning and at-risk family members.

Individual variants have a 50% probability of being passed on to each respective offspring.

## RECOMMENDATION

---

To determine whether the detected variant in gene *LZTR1* is *de novo* in your patient, testing of both parents regarding this variant is recommended, if possible. Testing of asymptomatic family members may only be performed after genetic counseling.

We recommend further clinical evaluation and management according to the current guidelines for *LZTR1*-associated schwannomatosis (Dhamija et al., 2018, PMID: 29517885, GeneReviews).

According to § 10 of the German Genetic Diagnostics Legislation, appropriate genetic counseling should be offered with all diagnostic genetic testing. Following the identification of the molecular cause of a genetic disease, genetic counseling has to be offered.

Medical report written by: Scientist 1

Proofread by: Scientist 2

With kind regards,

Dr. med. Dr. rer. nat. Saskia Biskup  
Dr. med. Friedmar Kreuz, M.A.

Consultant for Human Genetics

Dr. rer. nat. Heinz-Dieter Gabriel  
PD Dr. biol. hum. Christiane Maier  
Dr. rer. nat. Christian Wilhelm  
Dr. rer. nat. Martin Ritthaler

Diagnostics

## ADDITIONAL INFORMATION

**Requested Regions** *LZTR1, NF1, NF2, SMARCB1, SPRED1* (Neurofibromatosis 1 and related disorders)

**Methods** **Sequencing:** Protein-coding regions, as well as flanking intronic regions and additional disease-relevant non-coding regions, were enriched using in-solution hybridization technology, and were sequenced using the Illumina NovaSeq6000 system. In order to provide a second, independent validation, one or more rare variant(s) identified within the NGS data were additionally sequenced using conventional Sanger sequencing.

**NGS based CNV-Calling:** (only applicable for nuclear encoded genes) Copy number variations (CNV) were computed on uniquely mapping, non-duplicate, high-quality reads using an internally developed method based on sequencing coverage depth. Briefly, we used reference samples to create a model of the expected coverage that represents wet-lab biases as well as inter-sample variation. CNV calling was performed by computing the sample's normalized coverage profile and its deviation from the expected coverage. Genomic regions are called as variant if they deviate significantly from the expected coverage.

Please note that next generation sequencing based detection of copy number variations has lower sensitivity/specificity than a direct quantification method, e.g. MLPA. Copy-neutral structural aberrations can not be detected using this method (e.g. balanced translocations and balanced inversions). The absence of reported CNVs therefore does not ultimately guarantee the absence of CNVs.

**Computational Analysis:** Illumina bcl2fastq2 was used to demultiplex sequencing reads. Adapter removal was performed with Skewer. The trimmed reads were mapped to the human reference genome (hg19) using the Burrows Wheeler Aligner. Reads mapping to more than one location with identical mapping score were discarded. Read duplicates that likely result from PCR amplification were removed. The remaining high-quality sequences were used to determine sequence variants (single nucleotide changes and small insertions/deletions). The variants were annotated based on several internal as well as external databases.

**Diagnostic data analysis:** Variants were classified and reported based on ACMG/ACGS-2020v4.01 guidelines (Richards et al., 2015, PMID: 25741868, <https://www.acgs.uk.com/quality/best-practice-guidelines/>).

Only variants (SNVs/Small Indels) in the coding region and the flanking intronic regions ( $\pm 8$  bp) with a minor allele frequency (MAF)  $< 1.5\%$  are evaluated. Known disease-causing variants (according to HGMD) are evaluated in up to  $\pm 30$  bp of flanking regions and up to  $5\%$  MAF. Minor allele frequencies are taken from public databases (e.g. gnomAD) and an in-house database. If an acceptable sequencing-depth per base is not achieved by high-throughput sequencing, our quality guidelines demand local re-sequencing using classical Sanger-technology. Candidate CNV calls are evaluated manually. Potentially pathogenic findings are validated with a second method, like MLPA, on a case by case basis.

In this case, 99.43% of the targeted regions were covered by a minimum of 30 high-quality sequencing reads per base. **The evaluation of variants is dependent on available clinical information at the time of analysis.** The medical report contains all variants not classified as benign or likely benign according to current literature. Synonymous variants in mitochondrially encoded genes are classified as benign. *In silico* prediction of variants listed in the chart above is calculated on the basis of the output of the programs Mutation Taster, fathmm, Mutation Assessor, SIFT, fathmm-MKL coding, LRT, and PROVEAN according to the following criteria: 100% consensus = pathogenic/benign,  $\geq 75\%$  consensus = mostly pathogenic/benign, consensus  $< 75\%$  or no prediction possible = inconsistent. SpliceAI was utilized to evaluate the consequence of variants on splicing (thresholds: 0.8-1 "splice effect", 0.6-0.8 "possible splice effect",  $< 0.6$  "no splice effect"; Jaganathan et al., 2019, PMID: 30661751). The prediction of a splice effect for missense variants is only indicated if a threshold of 0.8 is reached. This prediction can be complemented with additional *in silico* predictions in individual cases.

Variants are named according to the HGVS recommendations without any information regarding the cis or trans configuration.

The sample fulfilled our quality criteria upon arrival and during/after each processing step in the laboratory.

The procedure described above was developed and validated in-house (Laboratory developed test; LDT).

**Communication, dissemination and usage of this report for scientific purposes is only permitted in accordance with the German Genetic Diagnostics Legislation.**